GleamWall
中文EN

PCRX Pacira BioSciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1396814 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.7%
TTM net income YoY76.0%
TTM EPS YoY97.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR75.5%

Margins

Gross margin78.7%
Operating margin4.8%
Net margin5.1%
FCF margin22.7%
EBITDA margin12.4%

Returns

ROE5.2%
ROA3.0%
ROIC (approx.)4.2%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets40.8%
Debt / equity0.41x
Current ratio4.68x
Interest coverage2.54x

Cash quality & payout

Operating cash flow / net income4.69x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$726.41M$700.97M
Cost of revenue$149.75M$170.43M
Gross profit$576.66M$530.54M
R&D expense$117.31M$81.58M
SG&A expense$368.76M$294.10M
Operating income$19.19M-$73.37M
Interest expense$17.45M$16.57M
Pretax income$16.87M-$63.11M
Income tax$9.84M$36.45M
Net income$7.03M-$99.56M
EBITDA$110.21M$5.41M
EPS (basic)0.16-2.15
EPS (diluted)0.16-2.15
Weighted avg. shares (diluted)45.04M46.24M
Balance sheet
Cash & equivalents$158.54M$276.77M
Short-term investments$79.88M$207.84M
Receivables$124.07M$113.30M
Inventory$152.86M$125.28M
Current assets$547.97M$745.13M
PP&E, net$140.69M$167.17M
Goodwill$20.21M$0
Intangibles$368.10M$425.97M
Total assets$1.26B$1.55B
Current liabilities$120.59M$309.92M
Short-term debt$0$201.78M
Long-term debt$372.19M$383.55M
Total debt$372.19M$585.32M
Total liabilities$571.81M$775.17M
Shareholders' equity$693.11M$778.35M
Net debt$213.64M$308.55M
Shares outstanding41.12M46.24M
Cash flow statement
Operating cash flow$151.99M$189.39M
Capital expenditure$15.33M$10.64M
Free cash flow$136.66M$178.75M
Investing cash flow$99.48M-$83.28M
Financing cash flow-$369.63M$17.36M
Depreciation & amortization$91.02M$78.78M
Stock-based compensation$57.50M$51.17M
Share buybacks$148.33M$25.00M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.